ABCB1 variant provides important leads for pharmacogenetics of epilepsy

The study by Taur et al. is important for two reasons - 1) The authors have evaluated the key drug-metabolizing enzyme genes CYP2C9, CYP2C19 (Pharmacokinetic) and drug target gene ABCB1 (Pharmacodynamic) and secondly, they have attempted to correlate the activity of P-glycoprotein along with the pla...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of postgraduate medicine 2014-07, Vol.60 (3), p.239
Hauptverfasser:	Phani, M N, Satyamoorthy, K
Format:	Artikel
Sprache:	eng
Schlagworte:	Anticonvulsants - pharmacology ATP Binding Cassette Transporter 1 - genetics ATP-Binding Cassette, Sub-Family B, Member 1 - genetics Convulsions & seizures Cytochrome P-450 CYP2C19 - genetics Cytochrome P-450 CYP2C9 - genetics Drug Resistance - genetics Drug therapy Enzymes Epilepsy Epilepsy - drug therapy Female Genes Genetic aspects Genetic variation Humans Male Pharmacogenetics Studies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The study by Taur et al. is important for two reasons - 1) The authors have evaluated the key drug-metabolizing enzyme genes CYP2C9, CYP2C19 (Pharmacokinetic) and drug target gene ABCB1 (Pharmacodynamic) and secondly, they have attempted to correlate the activity of P-glycoprotein along with the plasma drug concentrations for treatment response in patients with epilepsy.
ISSN:	0022-3859 0972-2823